Mortality Benefit Seen With Statins in Patients with Vasospastic Angina
WASHINGTON, DC—Treatment with statins was associated with a lower mortality rate in patients with vasospastic angina, according to a new study presented at the ACC.17 Scientific Session.
While considered a standard treatment for atherosclerotic cardiovascular disease, the benefits of statins in patients with vasospastic angina are still unknown. To investigate the long-term outcomes of statin therapy in these patients, researchers from the Heart Institute, University of Ulsan College of Medicine, Seoul, South Korea, used the ASAN VSA Registry, which enrolled 1779 patients with vasospastic angina between March 1996 and September 2014.
At enrollment, 47.2% of patients were being treated with statins. During follow-up (median duration of 8.1 years), the statin group showed a lower incidence rate of death from any cause (the primary endpoint) (0.67% patient-years vs. 1.27% patient-years; adjusted hazard ratio [aHR] 0.51; 95% CI: 0.35–0.74; P<0.001).
The incidence rate of cardiac death was also lower in the statin group (0.07% patient-years vs. 0.5% patient-years; aHR 0.10; 95% CI: 0.03–0.32; P<0.001).
"Statin therapy should therefore be considered as the standard treatment on top of vasodilator therapy for the treatment of VSA," concluded lead author Cheol Hyun Lee.